DigiPath, Inc®, a provider of affordable, innovative and reliable digital pathology solutions, and Medica Corporation, a leading medical device designer and manufacturer with FDA and ISO compliant manufacturing facilities, have entered into a distribution agreement allowing DigiPath to assist their digital pathology customers in adopting EasyCell assistant, an affordable and FDA cleared digital hematology solution.
EasyCell assistant uses image-processing and pattern-recognition technology to automatically locate white cells on a blood smear, pre-classify the cells and then present them to a technician for review on an LCD display. EasyCell locates and pre-classifies normal white blood cells, smudge cells, NRBC’s and variant lymphocytes. Images of these cells are then displayed, grouped by cell type, for confirmatory review.
“Our customers have been asking to augment their digital pathology deployments with automated hematology solutions,” said Eric Stoppenhagen, President of DigiPath,Inc. “EasyCell assistant complements our existing affordable, innovative, and reliable solution portfolio.”
“DigiPath’s success in promoting digital pathology adoption will be extended by complementing their product offering with an affordable hematology solution. I am delighted to have DigiPath as a distribution partner for EasyCell assistant,” stated Robert H. Hagopian, President of Medica Corporation.
About DigiPath, Inc.
DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPath’s advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 500 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide.
About Medica Corporation
For over 25 years, Medica has used its proprietary knowledge of sensor technology to manufacture a line of easy-to-use, easy-to-maintain, low-cost blood testing analyzers. Medica is actively engaged in the development of new technology to design future analyzers with the same ease-of-use. The Company’s rapid growth is a result of strategic focus on the worldwide need to lower healthcare costs.
SAFE HARBOR STATEMENT
This Press Release may contain certain forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. DigiPath has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect DigiPath's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause DigiPath's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. DigiPath undertakes no obligation to update or provide advice in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.